ReviewESMO open2026
Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gaps.
Review in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced nausea and vomiting (CINV) remains a clinically significant adverse event in patients receiving moderately emetogenic chemotherapy (MEC). Although the delayed phase is conventionally defined as 24-120 h after chemotherapy, symptoms may persist beyond this timeframe. However, the extent to which long-delayed CINV (>120 h) has been evaluated in prospective MEC studies remains unclear. PATIENTS AND
methodsThis study aimed to systematically map the definitions and reporting of delayed and long-delayed CINV in prospective MEC trials, with an exploratory quantitative synthesis of reported CR rates across assessment periods. PubMed/Cochrane Library/Medical Online/Ichushi-Web was used to search for studies published between January 2000 and December 2025. Eligible studies reported CR rates and clearly defined delayed-phase outcomes. A meta-analysis of proportions was carried out to estimate the pooled CR rates in the acute, delayed, and long-delayed phases.
resultsTwenty-six studies comprising 15 phase III and 11 phase II trials were included. The delayed phase was consistently defined as 24-120 h, with 80.8% of studies restricting outcome assessment to this timeframe. Only a limited number of studies evaluated CINV beyond 120 h. In these studies, the pooled CR rate declined from 71% during the conventional delayed phase to 62% during the long-delayed phase. Exploratory subgroup analyses suggested higher pooled CR rates with neurokinin-1 receptor antagonist-containing regimens and in studies including older patients, whereas lower rates were reported in studies including higher proportions of female patients.
conclusionsIn prospective trials, delayed CINV is almost uniformly evaluated within 120 h. CR rates decline in the long-delayed phase, suggesting that conventional endpoints may overestimate antiemetic efficacy. Extending assessment beyond 120 h may provide a more comprehensive characterization of CINV and should be considered in future prospective trials, particularly for newer agents associated with prolonged emetic risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.